ASKA Pharmaceutical Holdings Co (TSE:4886) EV-to-EBIT : 5.64 (As of Jun. 09, 2024)

ASKA Pharmaceutical Holdings Co EV-to-EBIT Chart

ASKA Pharmaceutical Holdings Co Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-EBIT	Get a 7-Day Free Trial							5.24	6.09	4.87	4.70	-

Competitive Comparison of ASKA Pharmaceutical Holdings Co's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, ASKA Pharmaceutical Holdings Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ASKA Pharmaceutical Holdings Co's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, ASKA Pharmaceutical Holdings Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where ASKA Pharmaceutical Holdings Co's EV-to-EBIT falls into.

ASKA Pharmaceutical Holdings Co EV-to-EBIT Calculation

ASKA Pharmaceutical Holdings Co's EV-to-EBIT for today is calculated as:

ASKA Pharmaceutical Holdings Co's current Enterprise Value is 円55,818 Mil.
ASKA Pharmaceutical Holdings Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was 円9,902 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ASKA Pharmaceutical Holdings Co  (TSE:4886) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

ASKA Pharmaceutical Holdings Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

ASKA Pharmaceutical Holdings Co's Enterprise Value for the quarter that ended in Dec. 2023 was 円40,208 Mil.
ASKA Pharmaceutical Holdings Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was 円9,902 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ASKA Pharmaceutical Holdings Co EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of ASKA Pharmaceutical Holdings Co's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

ASKA Pharmaceutical Holdings Co (TSE:4886) Business Description